Physician profile
Manish Tandon
NPI 1417021437
$7,040.42
in general payments reported to CMS, 2019-2025
34 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $424 · 2021: $803 · 2022: $1,693 · 2023: $955 · 2024: $1,451 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Gift: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.62 |
| Gift | $163.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,185.41 | 2019-2025 | Viberzi, Linzess |
| Pfizer INC. | $621.17 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $614.87 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $584.37 | 2019-2024 | Trulance |
| Celgene Corporation | $548.62 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $449.11 | 2021-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $439.40 | 2019-2025 | Suflave, Sutab |
| Janssen Biotech, INC. | $427.72 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $401.91 | 2019-2025 | |
| Boston Scientific Corporation | $192.76 | 2022-2023 | |
| Novo Nordisk INC | $151.67 | 2019-2024 | Wegovy |
| Redhill Biopharma INC. | $150.80 | 2021-2022 | |
| Ardelyx, INC. | $136.94 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $134.27 | 2024 | Omvoh, Mounjaro, Zepbound |
| Covidien LP | $124.92 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $116.52 | 2019 | |
| Merck Sharp & Dohme LLC | $114.02 | 2019-2021 | |
| Genzyme Corporation | $106.14 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $63.49 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $61.02 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $49.16 | 2024 | Dupixent |
| Alfasigma USA, INC. | $45.94 | 2020 | |
| Allergan, INC. | $42.64 | 2019-2021 | |
| Echosens North America, INC. | $40.15 | 2020-2023 | Fibroscan |
| Lucid Diagnostics INC. | $38.42 | 2023-2024 | |
| Madrigal Pharmaceuticals | $37.08 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $24.35 | 2020 | |
| Acacia Pharma INC | $22.40 | 2021 | |
| Shire North American Group INC | $21.97 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.97 | 2021 | |
| Organon LLC | $20.18 | 2024 | |
| Conmed Corporation | $19.86 | 2025 | System 2450 |
| Dynavax Technologies Corporation | $17.24 | 2019 | |
| Medtronic, INC. | $14.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Tandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.